MXPA06013121A - Metodo y composicion para el tratamiento de rinitis. - Google Patents

Metodo y composicion para el tratamiento de rinitis.

Info

Publication number
MXPA06013121A
MXPA06013121A MXPA06013121A MXPA06013121A MXPA06013121A MX PA06013121 A MXPA06013121 A MX PA06013121A MX PA06013121 A MXPA06013121 A MX PA06013121A MX PA06013121 A MXPA06013121 A MX PA06013121A MX PA06013121 A MXPA06013121 A MX PA06013121A
Authority
MX
Mexico
Prior art keywords
composition
treating rhinitis
rhinitis
compositions
pharmaceutical
Prior art date
Application number
MXPA06013121A
Other languages
English (en)
Spanish (es)
Inventor
Anders Carlsson
Lena Pereswetoff-Morath
Original Assignee
Biolipox Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolipox Ab filed Critical Biolipox Ab
Publication of MXPA06013121A publication Critical patent/MXPA06013121A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA06013121A 2004-05-11 2005-05-06 Metodo y composicion para el tratamiento de rinitis. MXPA06013121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/842,433 US20050255154A1 (en) 2004-05-11 2004-05-11 Method and composition for treating rhinitis
PCT/GB2005/001758 WO2005107711A2 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis

Publications (1)

Publication Number Publication Date
MXPA06013121A true MXPA06013121A (es) 2007-05-16

Family

ID=34968224

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06013121A MXPA06013121A (es) 2004-05-11 2005-05-06 Metodo y composicion para el tratamiento de rinitis.

Country Status (24)

Country Link
US (3) US20050255154A1 (enExample)
EP (1) EP1771155B1 (enExample)
JP (1) JP4976283B2 (enExample)
CN (2) CN1984643A (enExample)
AT (1) ATE550015T1 (enExample)
AU (1) AU2005239866B2 (enExample)
BR (1) BRPI0510778B8 (enExample)
CA (1) CA2536728C (enExample)
CY (1) CY1112981T1 (enExample)
DK (1) DK1771155T3 (enExample)
EA (1) EA014752B1 (enExample)
ES (1) ES2395130T3 (enExample)
HR (1) HRP20120484T1 (enExample)
IL (1) IL179012A (enExample)
ME (1) ME01436B (enExample)
MX (1) MXPA06013121A (enExample)
NO (1) NO335840B1 (enExample)
NZ (1) NZ550412A (enExample)
PL (1) PL1771155T3 (enExample)
PT (1) PT1771155E (enExample)
RS (1) RS52311B (enExample)
SI (1) SI1771155T1 (enExample)
WO (1) WO2005107711A2 (enExample)
ZA (1) ZA200608407B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060484A1 (es) 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
PT1888033E (pt) 2005-06-09 2014-05-15 Meda Ab Método e composição para tratamento de distúrbios inflamatórios
FR2900576B1 (fr) * 2006-05-03 2008-09-19 Centre Nat Rech Scient Procede de concentration extemporanee et reversible de liposomes.
US20090269393A1 (en) * 2006-06-12 2009-10-29 Jubliant Organosys Limited Chewable Bilayer Tablet Formulation
AU2008326800A1 (en) * 2007-11-16 2009-05-28 Baylor College Of Medicine Phospholipid compositions and uses thereof
WO2009148955A2 (en) * 2008-05-29 2009-12-10 Mdrna, Inc Multi-arm amines and uses thereof
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
MX2011009802A (es) 2009-03-17 2011-11-02 Aciex Therapeutics Inc Formulaciones oftalmicas de cetirizina y metodos de uso.
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8524692B2 (en) * 2010-04-29 2013-09-03 Georgia Health Sciences University Research Institute, Inc. Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof
EP2598143A1 (en) * 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
CN102525921B (zh) * 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
KR101475776B1 (ko) * 2012-08-24 2014-12-24 영진약품공업 주식회사 이중 포화 인지질을 포함하는 안정한 피부 외용 조성물
CN104887635B (zh) * 2015-05-20 2019-06-11 苏州东瑞制药有限公司 一种盐酸西替利嗪片及其制备工艺
CN113434592A (zh) * 2018-10-31 2021-09-24 创新先进技术有限公司 基于区块链的数据存证方法及装置、电子设备
US20220395438A1 (en) * 2019-11-04 2022-12-15 Universitat Autonoma De Barcelona Tooth whitening composition
CN114392235B (zh) * 2022-01-28 2023-06-27 成都大学 盐酸西替利嗪眼用脂质体、原位凝胶及其制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
GB8522964D0 (en) 1985-09-17 1985-10-23 Biocompatibles Ltd Aerosol
AU7543887A (en) 1986-06-12 1988-01-11 Liposome Company, Inc., The Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
EP0249561B1 (en) 1986-06-12 1992-05-13 The Liposome Company, Inc. Compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
SE8603812D0 (sv) 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
JPH04505616A (ja) 1989-05-15 1992-10-01 ザ　リポソーム　カンパニー，インコーポレイテッド プロトン勾配によるリポソームへの薬剤の蓄積
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
KR100241300B1 (ko) * 1993-11-16 2000-03-02 Sheldon A. Schaffer 활성물질의 조절된 방출성을 갖는 소포
DE4341472A1 (de) 1993-12-02 1995-06-08 Schering Ag Verfahren zur Erhöhung der Stabilität von hydrophile Wirkstoffe enthaltenden Liposomensuspensionen
DE69528355T2 (de) * 1994-02-04 2003-05-15 Lipocore Holding Ab Stockholm Doppelschicht-zusammensetzungen aus digalactosyldiacylglycerol enthaltendem galactolipid
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
WO1996009297A1 (en) * 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition
AU6392496A (en) 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
WO1997046243A1 (en) 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5958378A (en) 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
TW497974B (en) 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
CA2281789A1 (en) 1997-04-30 1998-11-05 Warner-Lambert Company Topical nasal antiinflammatory compositions
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
JP2002507917A (ja) * 1997-07-04 2002-03-12 トルサナ オステオポロシス ダイアグノスティクス アクティーゼルスカブ 脊椎動物の骨質又は骨格状態を評価するための方法
TR200101790T2 (tr) * 1998-12-23 2001-10-22 Idea Ag. Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül
GR1003359B (el) 1998-12-24 2000-04-10 �.�. ����������� �.�.�.�. Λιποσωμιακο νιφλουμικο οξυ - νεο διαδερμικο αντιφλεγμονωδες φαρμακο [κεφαλη ψαροτουφεκου
US6613352B2 (en) * 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
EP1427393A2 (de) * 2000-05-02 2004-06-16 Pharmacept GmbH Wirkstoffhaltige liposome
AU3169702A (en) 2000-12-07 2002-06-18 Yamanouchi Europ Bv Composition for treatment of inflammatory disorders
US20030144336A1 (en) * 2001-08-27 2003-07-31 Pfizer Inc. Method of selecting nonsedating H1-antagonists
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
ATE317268T1 (de) 2001-12-05 2006-02-15 Alcon Inc Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis
WO2003097100A1 (en) 2002-05-15 2003-11-27 Engelbrecht, Edna Topical composition for the treatment of inflammatory conditions of the skin
EP1371362A1 (en) 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
WO2004012675A2 (en) * 2002-08-02 2004-02-12 University Of Massachusetts Lipid binding molecules and methods of use
JP2004168709A (ja) * 2002-11-20 2004-06-17 Nidek Co Ltd 抗アレルギー点眼点鼻用組成物
WO2004069338A1 (en) * 2003-01-31 2004-08-19 Schering Corporation Use of combinations of h1 and h3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
PT2286794T (pt) 2003-10-15 2016-07-13 Syncore Biotechnology Co Ltd Uso de lipossomas catiónicos contendo placlitaxel
JP2005170923A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法

Also Published As

Publication number Publication date
HRP20120484T1 (hr) 2012-07-31
US20180104238A9 (en) 2018-04-19
ME01436B (me) 2012-12-31
BRPI0510778A (pt) 2007-11-20
CA2536728A1 (en) 2005-11-17
AU2005239866A1 (en) 2005-11-17
US9980959B2 (en) 2018-05-29
EP1771155B1 (en) 2012-03-21
AU2005239866B2 (en) 2010-03-04
ATE550015T1 (de) 2012-04-15
EA200602092A1 (ru) 2007-06-29
ES2395130T3 (es) 2013-02-08
CA2536728C (en) 2011-02-01
CN103271910B (zh) 2018-11-06
IL179012A0 (en) 2007-03-08
CN1984643A (zh) 2007-06-20
EA014752B1 (ru) 2011-02-28
CN103271910A (zh) 2013-09-04
HK1098960A1 (en) 2007-08-03
PL1771155T3 (pl) 2012-08-31
SI1771155T1 (sl) 2012-09-28
DK1771155T3 (da) 2012-07-09
NO20064521L (no) 2007-02-06
RS52311B (sr) 2012-12-31
US20130039969A1 (en) 2013-02-14
BRPI0510778B1 (pt) 2020-03-10
US20070026058A1 (en) 2007-02-01
BRPI0510778B8 (pt) 2021-05-25
EP1771155A2 (en) 2007-04-11
JP2007537220A (ja) 2007-12-20
IL179012A (en) 2014-11-30
NO335840B1 (no) 2015-03-02
WO2005107711A2 (en) 2005-11-17
NZ550412A (en) 2010-08-27
JP4976283B2 (ja) 2012-07-18
PT1771155E (pt) 2012-05-15
ZA200608407B (en) 2007-12-27
US20050255154A1 (en) 2005-11-17
WO2005107711A3 (en) 2006-03-16
CY1112981T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
CY1112981T1 (el) Μεθοδος και συνθεση για την αγωγη της ρινιτιδας
WO2006131737A3 (en) Method and composition for treating inflammatory disorders
BRPI0415858A (pt) compostos de medicamentos terapêuticos modificados por tocoferol
NO20064584L (no) Tetrahydropyridoindolderivater
ATE535257T1 (de) Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin
NO20065904L (no) Terapeutiske forbindelser
GEP20094781B (en) Sulfonamide derivatives for the treatment of diseases
CY1106409T1 (el) Παραγωγα κινολινης
ZA200709296B (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycolotonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
DE60119976D1 (en) Thixotropes nasenspray
WO2007035121A3 (en) Isoflavones for treating mucopolysaccharidoses
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
NO20063881L (no) Behandling av rhinitt med antikolinergier alene i kombinasjon med antihistaminer fosfodiesterase 4 inhibitorer eller kortikosteroider
WO2007076310A3 (en) Iontophoretic transdermal delivery of nicotine salts
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
PL1668021T3 (pl) Nowe związki tioksylozy, sposób ich przygotowania, zawierające je kompozycje farmaceutyczne i ich zastosowanie w lecznictwie
NO20060655L (no) 2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn
PL1874410T3 (pl) Odbarwiająca lub rozjaśniająca kompozycja kosmetyczna zawierająca co najmniej jedną oksazolinę jako składnik aktywny
UA92908C2 (ru) Соединения, производные от 5-тиоксилозы, и их терапевтическое применение
WO2004103985A3 (en) Derivatives of fusarochromanone as therapeutic agents
MX2009003253A (es) Derivados de 5-tioxilopiranosa y uso de los mismos para tratamiento.
WO2006076598A3 (en) Bicyclic heterocycles as cannabinoid receptor modulators
MX2009003254A (es) Nuevos derivados de 5-tioxilopiranosa.
IL163938A0 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye

Legal Events

Date Code Title Description
FG Grant or registration